Baobab Powder Market is Likely to Grow at a CAGR of 6.2% CAGR through 2027, Future Market Insights Inc.

The global Baobab Powder Market is anticipated to witness robust growth during the assessment period. Future Market Insights studies the factors driving the popularity and adoption of baobab powder across the globe. Consumers today are becoming aware about the benefits of baobab powder, which in turn is surging the demand for baobab powder based products such as cereals and bars.

Due to the fact that baobab powder has numerous skin benefits, it is used as an ingredient in various anti-ageing creams and helps protect the skin against high or low temperatures, rejuvenates the skin cells, moisturizes the skin and prevents damage from free radicals. Also, as baobab powder is a rich source of calcium and potassium, it is also found in products such as cereals, bars and jellies. Owing to its wide-ranging beneficial properties, the consumption of baobab powder is growing across the globe.

View our PDF a Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3333

Segmental Forecast of the global baobab powder market

The global baobab powder is segmented on the basis of product type (organic baobab powder, conventional baobab powder), end use (industrial, retail), sales channel (direct sales, indirect sales) and region.

Forecast by Product Type: Organic baobab powder segment is expected to register the highest CAGR during the forecast period. The organic baobab powder segment is estimated to be valued at US$ 8,544.2 Mn by 2027 end and is expected to expand at a CAGR of 6.5% over the forecast period.

Forecast by End Use: The retail segment is estimated to account for the highest value share of 65.2% in 2017 and is projected to reach a market valuation of US$ 6,545.1 Mn by 2027 end, registering a CAGR of 6.3% over the forecast period.

Forecast by Sales Channel: The indirect segment is estimated to account for the highest value share of 75.4% in 2017. This segment is estimated to be valued at US$ 7,602.1 Mn by 2027 end and is expected to expand at a CAGR of 6.3% over the forecast period.

Forecast by Region: North America followed by Western Europe will be the leading markets in the global baobab powder market with an anticipated value share of about 30% and 25% respectively by the end of 2027. North America will witness the highest regional CAGR of 6.8% during the forecast period.

Have a Conversation with Analyst@
https://www.futuremarketinsights.com/ask-question/rep-gb-3333

Competitive Landscape

The report profiles some of the top companies operating in the global baobab powder market including:

  • EcoProducts
  • Baobab Fruit Company Senegal
  • B’Ayoba (Pvt) Ltd
  • Organic Africa, Aduna Limited
  • Etude House
  • Woodland Foods
  • Powbab Inc
  • ATACORA
  • Halka B. Organics
  • Indigo Herbs LTD and Organic Burst UK Ltd.

Companies are focussing on addressing customer centric product demand by expanding their product portfolio and introducing a variety of products in the global market. Suppliers are entering into long-term contracts with baobab products manufacturers to avoid increase in product prices, and baobab manufacturers are also benefitting from these long-term contracts with suppliers as it helps them sustain their operations.

If Our Report Has Not Included the Data That You are Looking For, You Can Reach Out to Our Analysts and Get Segments Customized:  https://www.futuremarketinsights.com/customization-available/rep-gb-3333

Global Baobab Powder Market Forecast 2017-2027

Future Market Insights predicts the global baobab market to be valued at about US$ 5,483 Mn by the end of 2017 and will continue to grow at a CAGR of 6.2% during the period of study to reach a market valuation of about US$ 10,004 Mn by the end of the forecast period.

Competitive Landscape

The report profiles some of the top companies operating in the global baobab powder market including:

  • EcoProducts
  • Baobab Fruit Company Senegal
  • B’Ayoba (Pvt) Ltd
  • Organic Africa, Aduna Limited
  • Etude House
  • Woodland Foods
  • Powbab Inc
  • ATACORA
  • Halka B. Organics
  • Indigo Herbs LTD and Organic Burst UK Ltd.
    Companies are focussing on addressing customer centric product demand by expanding their product portfolio and introducing a variety of products in the global market. Suppliers are entering into long-term contracts with baobab products manufacturers to avoid increase in product prices, and baobab manufacturers are also benefitting from these long-term contracts with suppliers as it helps them sustain their operations.

About FMI

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse Other Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Aquafeed Market is Expected to Increase at a CAGR of 6.1% through 2032 | Future Market Insights Inc.

The aquafeed market is set to witness growth at a CAGR of 6.1% and is anticipated to reach a valuation of around USD 80.9 billion by 2032.

The aquafeed market is predicted to grow fast as fish farming operations expand. The market for plant-based aquafeed is anticipated to be driven over the forecast period by manufacturers’ rising demand for natural and organic feed products, which is currently the newest industry trend.

Check the sample report available in PDF format@ https://www.futuremarketinsights.com/reports/sample/rep-gb-4540

Furthermore, the use of organic fish feed allows aquatic animals to be raised in a proper and moral manner. Given that consumers’ preference for organic food has grown significantly in recent years, it is projected that an increase in the production of organic feed is likely to support a rise in sales of aquafeed.

Rising consumer spending on fish and fish-related goods, such as fish oil, fish meal, and fish silage, as well as rising seafood consumption, are expected to result in increased aquaculture production.

The rapid price fluctuations of the raw ingredients required to make aquafeed could hinder its ability to increase its market share. The demand for aquafeed is expected to remain strong in China and India throughout the projection period, due to the dramatic growth in fish production rate.

Key Takeaways from Market Study

  • The aquafeed market is currently holding a market share of US$ 44.7 billion.
  • By 2032, the aquafeed market is expected to reach US$ 80.9 billion.
  • Based on species, the fish category holds the largest market share in aquafeed.
  • The market is dominated by amino acids, which generate more than 32% of total revenue.
  • In 2017, the aquaculture business in the United States produced 283 million kilograms of produce worth USD 1.4 billion.
  • Japan’s expanding demand for aquafeed is being driven by rising seafood consumption and improved public understanding of the health advantages of seafood.

Buy Now to Gain Access to Detailed Information about Each Segment: https://www.futuremarketinsights.com/checkout/4540

 “The aquafeed industry is being driven by rising global fish consumption and a growth in processed seafood consumption as a result of rising middle-class prosperity in emerging economies. The demand for high-quality aqua feed, feed additives, and compound feed has increased as the aquaculture business has grown. Because feed sources are limited, the aqua feed market is expected to grow as the demand for seafood rises, resulting in greater farming,” says a Future Market Insights analyst.

Competitive Landscape

As a result of the positive impact of high intake on aquaculture productivity, demand for aquafeed is expected to grow at a faster rate. In order to enhance their market presence and client base, industry players are being forced to expand their product portfolios and distribution networks as the market grows.

Aquafeed manufacturers are always conducting research and development in order to give a wide range of natural and organic aquafeeds for use in the growth of a variety of species.

Have a Conversation with our Analyst@
https://www.futuremarketinsights.com/ask-question/rep-gb-4540

Recent Developments

  • ADM acquired Neovia (formerly InVivo NSA) (France) in January 2019 for USD 1.82 billion (Euro 1.54 billion). This acquisition would provide a strong platform for ADM’s future growth.
  • In November 2018, Cargill invested USD 70 million in Thailand to support the aquaculture and poultry industries there with cutting-edge technologies.

Explore More Valuable Insights

Future Market Insights, in its new report, offers an impartial analysis of the Aquafeed market, presenting historical data (2017-2021) and estimation statistics for the forecast period of 2022-2032.

The study offers compelling insights based on Species (Crustaceans, Fish), Form (Extruded, Powder, Liquid, Pellets), Function (Health, Digestion, Palatability, Special Nutrition), Ingredients (Marine, Land Animal, Veg/Grain, Carotenoid, Nutrients), Sales Channel (Direct Sales, Indirect Sales, Hypermarket, Supermarket, Wholesalers, Speciality Stores, Online), across seven major regions of the world.

About FMI

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse Other Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Primary Hyperoxaluria Treatment Market is anticipated to grow with an 8.6% CAGR from 2023 to 2033 | FMI Study

According to a new market research report published by Future Market Insights, the global Primary Hyperoxaluria Treatment Market is expected to grow at a CAGR of 8.6% during the forecast period of 2023 to 2033. The market is expected to surpass US$ 41 million in value terms by the end of the aforementioned forecast period.

One of the most promising treatments for primary hyperoxaluria is Lumasiran, a drug that was approved by the U.S. Food and Drug Administration (FDA) in 2020. Lumasiran works by targeting the underlying genetic cause of primary hyperoxaluria, helping to reduce the production of oxalate in the body. Clinical trials of Lumasiran have shown promising results, with patients experiencing significant reductions in urinary oxalate levels and a reduced risk of kidney stone formation.

Get Full PDF Sample Copy of Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16885

In addition to Lumasiran, there are several other treatments in development for primary hyperoxaluria. These include gene therapy approaches that aim to correct the underlying genetic mutation that causes the condition. There is also ongoing research into the use of existing drugs, such as potassium citrate, in the treatment of primary hyperoxaluria.

The market for primary hyperoxaluria treatment is expected to grow rapidly in the coming years as more therapies become available. This growth is being driven by a number of factors, including increasing awareness and diagnosis of the condition, the development of new treatments, and favorable reimbursement policies. North America is currently the largest market for primary hyperoxaluria treatment, accounting for a significant share of global sales. This is due in part to the high prevalence of primary hyperoxaluria in the region, as well as the strong healthcare infrastructure and favorable reimbursement policies.

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-16885

Key Takeaways from the Market Study

  • From 2018 to 2022, the primary hyperoxaluria treatment market grew at a CAGR of 5.2%.
  • The global primary hyperoxaluria treatment market is expected to grow with an 8.6% CAGR from 2023 to 2033.
  • As of 2033, the primary hyperoxaluria treatment market is expected to reach US$ 41.07 million.
  • According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
  • North America is expected to possess a 40% market share for the Primary Hyperoxaluria Treatment market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering primary hyperoxaluria treatment,” says an FMI analyst

Market Competition

Key players in the market include companies such as Competition Deep Dive,  Alnylum Pharma, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, along with healthcare providers and technology companies among other global players.

  • In 2020, the United States Food and Drug Administration (FDA) gave the green light to Oxlumo (lumasiran) as the initial treatment for primary hyperoxaluria type 1 (PH1), a rare hereditary disorder. This groundbreaking approval is the culmination of the work of specialists and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
  • The approval of Oxlumo was a result of input from patients, treating physicians, experts, and sponsors at a patient-focused drug development meeting and through other collaborative efforts. Oxlumo’s function is to reduce the production of oxalate in patients with PH1. The drug was evaluated in two separate trials in PH1 patients: a randomized, placebo-controlled trial in patients aged six years and older, and an open-label study in patients under six years old. The patients ranged in age from four months to 61 years at the start of treatment.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Primary Hyperoxaluria Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of type (type 1, type 2, and type 3), drug class (pyridoxine, potassium citrate, thiazides, and orthophosphates), route of administration (oral and intravenous), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) across seven major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa).

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16885

Key Segments Profiled in the Primary Hyperoxaluria Treatment Industry Survey

Type:

  • Type 1
  • Type 2
  • Type 3

Drug Class:

  • Pyridoxine
  • Potassium Citrate
  • Thiazides
  • Orthophosphates

Route of Administration:

  • Oral
  • Intravenous

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Unit Dose Manufacturing Market is projected to reach US$ 164 Billion by 2032

Global Unit Dose Manufacturing Market sales was held at around US$ 22 Billion in 2022. The report also forecasts a significant market growth of 22.4% between 2022 and 2032 to reach a valuation US$ 164 Billion. During the projected period from 2022 to 2032, Outsourcing is expected to generate the largest revenue, while Solid Unit Dose is expected to be the highest revenue-generating Filament, with a CAGR of 19.8% and 22.8%, respectively.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14770

The market growth is expected to be driven by the benefits of unit dose manufacturing, such as complete drug identification and preservation of the dosage form’s integrity until the time of administration. The FDA regulates unit dose-packed oral solid pharmaceuticals, and unit dosage repackaging has gained popularity, as unit dosages must be placed in containers for continuous use in hospitals. However, questions about their stability, formulation contamination, and product expiration have arisen as their popularity has grown.

Unit doses have also raised patient and staff safety standards by eliminating the possibility of erroneous dosing. They use electronic papers to facilitate speedy and effective monitoring, and it is easy to spot any broken containers when using liquid unit doses. Unit doses can also save consumers money on medications they do not need. The projected double-digit growth during the period of projection is expected to further increase the market size.

Key Takeaways from the Market Study

  • Global Unit Dose Manufacturing market is estimated to reach a market size of around US$ 22 Billion by 2022
  • Top Type being Outsourcing expected to grow at a CAGR of 19.8%.
  • Top Filament being Solid Unit Dose expected to grow at a CAGR of 22.8%.
  • With over 25% projected growth rate, Unit Dose Manufacturing revenue is expected to grow at fastest pace in Asia Pacific, during 2022 to 2032.

Benefits associated with manufacturing unit doses over packaging, and flourishing pharmaceutical industry, are expected to shape the overall Unit Dose Manufacturing market, comments a Future Market Insights analyst.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you@ https://www.futuremarketinsights.com/ask-question/rep-gb-14770

Competitive Landscape

A large number of regional and global players operate in the unit dose manufacturing market. A variety of strategies are being employed by companies to remain competitive. According to the market research analysis, partnerships and expansion have been the prominent development in Unit Dose Manufacturing market in recent year. Catalent Inc, Patheon, Unither, Mikart, Tapemark, Renaissance, Medical packaging Inc, Corden pharma, and American health packaging are the prominent providers of Unit Dose Manufacturing services.

  • In August 2020, Nanjing Ruinian Best Pharmaceutical Co. Ltd. was acquired by Unither Pharmaceuticals August 2020. This acquisition was reported to be focused on aiding Unither Pharmaceuticals expand in China through offering experience regarding medication research and single-dose sterile drugs without preservatives.

Future Market Insights’ Domain Knowledge in Healthcare Division

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned Healthcare domain team at Future Market Insights helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analysed the Healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

Key Companies Profiled:

  • Catalent Inc.
  • Patheon (Thermo fisher)
  • Unither
  • Tapemark
  • Mikart
  • Renaissance Lakewood, LLC
  • Medical packaging, Inc.
  • CordenPharma
  • American Health Packaging

For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/14770

Market Segments Covered in Unit Dose Manufacturing Industry Analysis

By Type:

  • In-House
  • Outsourcing

By Filament:

  • Solid Unit Dose
  • Liquid Unit Dose
  • Other Filaments

By Application:

  • Independent Pharmacies
  • Long Term Care Facility
  • Hospitals
  • Others

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Real World Evidence Solutions Market is expected to surpass US$ 110 billion by 2032

Future Market Insights recently published a report stating that the Real World Evidence Solutions Market size was valued at US$ 42.8 billion in 2022 and is predicted to achieve a CAGR of 10%, reaching US$ 110 billion by the end of 2032. This forecasted growth rate is higher than the historical CAGR of 8.6%. In the next ten years, the market is expected to offer an absolute dollar opportunity of US$ 67.2 billion.

During the 2022 to 2032 period, the Services segment is expected to garner an absolute dollar opportunity of US$ 41 Billion and account for the majority share of the global market, with a compound annual growth rate of 10.4%. The growth of the pharmaceutical and biotechnology industries is propelling the expansion of the market by increasing their use of real-world services. Clinical data collected during ongoing patient treatment or as part of a formal clinical trial program is a typical source of information in most medical studies.

Get a Sample PDF Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14765

The shift from volume-based to value-based care, favorable government policies, increased research and development spending, and a growing focus on end-to-end RWE services are driving the global market. By 2032, the Real World Evidence Solutions Market is projected to achieve a valuation of US$ 110 billion. The market is expected to expand further due to an increased emphasis on personalized healthcare, a rise in the frequency of chronic diseases, a growing geriatric population, and regulatory support for the implementation of RWE solutions.

Key Takeaways from the Market Study:

  • The Market is expected to grow at a CAGR of 10% which is significantly higher than its historical CAGR of 8.6%.
  • By the end of 2032, the global market for Real World Evidence Solutions will reach the valuation of US$ 110 Billion.
  • Within the period between 2022 and 2032, the market is expected to offer an absolute dollar opportunity of US$ 67.2 Billion.
  • The services segment leads the growth among components with a CAGR of 10.4%.
  • The US market for Real World Evidence Solutions constitutes a majority stake of 29.9% in the global market. It is expected to grow at a CAGR of 11.2% during the forecasted period of 2022 to 2032.
  • Drug Development and Approvals segment tops among the applications. Revenue through this segment is expected to grow at a CAGR of 10% during the forecast period.

Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-14765

Due to the pandemic induced business disruptions, companies were unable to undertake on-site surveillance or deliver services that required one to one interactions. This prompted the market players to implement several cost-cutting measures and business continuity tactics to allow remote access and monitoring of patients, comments a Future Market Insights analyst.

Market Segments Covered in Real World Evidence Solutions Market Study:

By Component:

  • Services
  • Data Sets
    • Clinical Settings Data
    • Claims Data
    • Pharmacy data
    • Patient-powered Data

By Application:

  • Reimbursement/Coverage & Regulatory Decision Making
  • Drug Development & Approvals
  • Medical Device Development & Approvals
  • Post Market Safety & Adverse Events Monitoring

By End-user:

  • Healthcare payers
  • Pharmaceutical & Medical Device Companies
  • Healthcare Providers
  • Other End-users

Competitive Landscape:

The Real World Evidence Solutions Market is driven by the Market players who are expanding their product portfolios by highly investing in the R&D and Product development areas. Furthermore, to retain their dominance in global market they are expanding by means of strategic mergers and acquisitions and creating the market presence in the untapped market across the globe. They are anticipated to take advantage of the increased awareness, improved infrastructure and increased regulatory approvals for the RWE solutions.

The key competitors in the Real World Evidence Solutions Market are –

  • Cegedim Health Data
  • IBM
  • Icon Plc.
  • IQVIA
  • Medpace
  • Oracle
  • Parexel International Corp.
  • PerkinElmer, Inc.
  • PPD, Inc.
  • Syneos Health

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/14765

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Interventional Cardiology Devices market is likely to register CAGR of 8.4% through 2032

The global Interventional Cardiology Devices market demand is expected to experience a 8.4% CAGR, growing from US$ 16.4 billion in 2022 to US$ 36.9 billion by 2032.

Factors driving market growth include the increasing elderly population leading to a rise in coronary artery disease prevalence, as well as the introduction of new and advanced products, and a rising incidence of diabetes.

Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14684

However, the availability of alternative therapies, as well as product failures and recalls, may limit market growth during the forecast period. Additionally, hospital visits have decreased due to lockdowns and social distancing, leading to lower sales for interventional cardiology products.

Leading companies in the Interventional Cardiology Devices market, including Boston Scientific, Medtronic, and Abbott, have reported revenue reductions in recent quarters. Despite this, the demand for interventional cardiology devices is expected to rise due to the high incidence of heart and circulation diseases, particularly in the United Kingdom.

Risk factors such as diabetes and hypertension also contribute to the demand for interventional cardiology equipment, with a rising prevalence of these conditions expected in major markets as the world’s population ages. Emerging markets such as India, China, and Brazil offer significant potential opportunities for the industry due to a large geriatric population and high diabetes incidence.

Of all interventional cardiology devices, angiography catheters hold the largest market share due to the high prevalence of coronary artery disease and growing awareness of early identification.

North America currently dominates the market due to factors such as growing diabetes prevalence, an aging population, reimbursement availability, and the presence of major corporations.

Get In Touch With Our Team For Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-14684

KEY TAKEAWAYS:

  • In the product sector, Angioplasty Stents from the marketing attribution software market is anticipated to flourish at the quickest CAGR of 8% through 2032.
  • With a CAGR of 7.9% through 2032, North America is predicted to grow significantly in the region segment of the marketing attribution software market.
  • The market size for marketing attribution software market in the United States is expected to reach US$ 12.9 Billion by 2032, growing at a CAGR of 8.2% through 2032.
  • China is anticipated to reach a market size of US$ 2.7 Billion in marketing attribution software by 2032, with a CAGR of 7.8% through 2032.
  • UK’s marketing attribution software market is anticipated to be worth US$ 1.5 Billion by 2032, with a CAGR of 7.5% through 2032.
  • Japan is expected to have a market size for marketing attribution software of US$ 2.1 Billion by 2032, with a CAGR of 6.7% through 2032.
  • By 2032, South Korea is expected to reach a market size of US$ 1.3 Billion in marketing attribution software, with a CAGR of 6.2% through 2032.

COMPETITIVE LANDSCAPE:

Medtronic (US), Boston Scientific Corporation (US), Abbott (US), Edward Lifesciences Corporation (US), Cardinal Health (US), iVascular (Spain), Becton, Dickinson, and Company (US), B. Braun Melsungen (Germany), Terumo Corporation (Japan), Biosensors International Group (Singapore), and BIOTRONIK SE & Co. KGaA are prominent Interventional Cardiology Devices market players (Germany).

Request Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-14684

Key Segments

By Product:

  • Angioplasty Balloons
    • Old/Normal Balloons
    • Drug-eluting Balloons
    • Cutting and Scoring Balloons
  • Angioplasty Stents
    • Drug-eluting Stents
    • Bare-mental Stents
    • Bioabsorbable Stents
  • Structural Heart Devices
    • Aortic Valve Therapy Devices
    • Other Therapy Devices
  • Catheters
    • Angiography Catheters
    • Guiding Catheters
    • IVUS/OCT Catheters
  • Plaque Modification Devices
    • Atherectomy Devices
    • Thrombectomy Devices
  • Hemodynamic Flow Alteration Devices
    • Embolic Protection Devices
    • Chronic Total Occlusion Devices
  • Other Devices
    • Guidewires
    • Vascular Closure Devices

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Neurosurgery Surgical Power Tools Market is anticipated to reach US$ 1.99 Billion by 2032, with a CAGR of 4.5%

The global Neurosurgery Surgical Power Tools Market sales is expected to exceeding US$ 1.99 billion by 2032, with a compound annual growth rate (CAGR) of 4.5%. Technological advancements and innovations in recent years have brought about significant changes in the healthcare industry, particularly in the field of neurosurgery. The ELAN 4, a next-generation tool integrated with pneumatic and electric power systems for brain and spine procedures, was awarded the iF DESIGN AWARD 2016 Category Medicine. Additionally, DePuy Synthes has introduced high-speed electric systems for their power tools. The introduction of new products and innovations is expected to drive market growth for Neurosurgery Surgical Power Tools.

To remain ahead of your competitors, request for a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8159

The growing elderly population worldwide has led to an increase in neurological diseases, which are now a major cause of death and disability. This is compounded by environmental factors. Power tools have become an important product in the medical devices industry, demonstrating promising results due to their versatility in various procedures, such as incision, drilling, sawing, and removal of hard and soft tissues and bone, for complex surgeries like neurosurgeries, orthopedic, cardiovascular, spine, and ENT surgeries.

The top two companies in the global Neurosurgery Surgical Power Tools market control over 56% of the market revenue, with tier-2 and tier-3 companies controlling the remaining market share. The market is highly consolidated, resulting in a high pricing premium for Neurosurgery Surgical Power Tools.

  • The majority of firms in the Neurosurgery Surgical Power Tools market are concentrating on the development of technologically advanced items and the expansion of their product portfolio.
  • According to FMI research, important enterprises will explore capacity expansion as well as a focus on developing a strong distribution network as additional growth efforts.
  • Companies are also producing new products to increase their product offerings in Asia Pacific’s rising markets in order to expand their clientele and acquire the highest market share in the emerging economies.

“As per FMI analysis, the manufacturers of Neurosurgery Surgical Power Tools are also expected to gain from increasing regulatory approvals. Over the last few years, leading players have received regulatory approvals across major geographic markets, which has enabled them to launch various products in the market”, Senior Analyst, FMI.

Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-8159

Geographically, North America Reigns Supreme in Global Neurosurgery Surgical Power Tools Landscape

North America and Europe have a major market share due to their larger installed base, accounting for around 64 percent of the total market.

Asia Pacific, on the other hand, is expected to give lucrative growth potential for makers of neurosurgical surgical power tools. Through 2028, APAC demand for neurosurgical surgical power tools is predicted to expand at a moderate CAGR of 4.1 percent.

The rapid sophistication of the healthcare and medical sectors in the Gulf economies has been cited as a key driver fueling the expansion of the MEA market.

FMI Identifies Key Trends Influencing Neurosurgery Surgical Power Tools Global Demand

Invasive procedures are giving way to minimally invasive surgeries, which have fewer adverse effects than traditional surgery. Few of the factors contributing to the expansion of minimally invasive surgeries, particularly neurosurgery treatments, are reduced post-operative pain and hospital stay, as well as speedier recovery.

Another significant trend discovered is the automation of neurosurgical surgical power instruments. When compared to traditional approaches, the automated neurosurgical power instruments are predicted to accelerate the speed of cranial surgeries by over 50 times. Aside from cutting operation time down from hours to minutes, such gadgets would also reduce the danger of infection and damage to sensitive tissues.

Because of their potential to create high speed and enter deeper regions of the brain, demand for smaller sized and light weight power tools will dominate all branches of neurosurgery.

Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-8159

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Esophagoscopes and Gastroscopes Market is slated to progress at a CAGR of 5.4% from 2023 to 2033

The global Esophagoscopes and Gastroscopes Market size, currently valued at US$ 1.2 billion, is expected to experience a compound annual growth rate (CAGR) of 5.4% and generate revenue of US$ 2.0 billion by 2033. Although these devices only account for 8% of the global endoscopes market, their sales are predicted to increase due to the growing preference for minimally invasive procedures, including laparoscopic equipment like arthroscopes, bronchoscopes, and laparoscopes.

Advancements in medical technology have led to a greater use of mechanical tools in diagnosing and treating esophageal disorders. This trend is expected to continue as the elderly population increases worldwide and cases of esophageal cancer rise. The expanding use of esophagoscopes in various diagnostic and surgical procedures is driving market growth, along with the growing prevalence of inflammatory bowel disease cases, which has fueled demand for devices with broad applications for early diagnosis.

To remain ahead of your competitors, request for a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3120

Despite the promising outlook for the market, contamination-induced infections, anesthesia-induced allergic reactions, and organ perforation pose significant risks to patients. These challenges are expected to limit market growth during the forecast period. Key players in the market should therefore prioritize the development of more efficient versions of these devices with fewer adverse effects.

Regional Insights:

The prevalence of gastrointestinal ailments has significantly increased in the United States. This is likely to rise more as obesity prevalence rises in the United States over the predicted period. Cases of stomach cancer, gastrointestinal haemorrhage, and functional gastrointestinal illnesses have all increased in the United States. As a result, the number of endoscopies conducted in the country has increased.

Some of the primary drivers driving the Esophagoscopes and Gastroscopes market in the United States include poor lifestyle choices, poor eating habits, and smoking. Over the projected period, sales of instruments such as laparoscopes, arthroscopes, bronchoscopes, gastroscopes, and so on are predicted to rise.

For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-3120

Competitive Landscape

Over the forecast period, exports of Esophagoscopes and Gastroscopes are predicted to increase from regions such as East Asia, South Asia, and the Pacific. The development of healthcare infrastructure, rising healthcare expenditure, rising technological proliferation, and other factors can all be related to the increase in demand in these locations.

Over the projection period, high birth rates in East Asia, South Asia, and the Pacific are likely to fuel demand growth for paediatric gastroscopes.

The MEA Esophagoscopes and Gastroscopes market has the smallest market share due to weak healthcare infrastructure in this area and less technological proliferation in medical operations. This is projected to alter over the forecast period, with the consumption of Esophagoscopes and Gastroscopes increasing.

Prominent players covered in the Global Esophagoscope and Gastroscope Market contain 

  • Shanghai AoHua Photoelectricity Endoscope Co. Ltd.
  • Olympus Corporation
  • Pentax Medical Company
  • Fujifilm Holdings Corp.
  • Karl Storz GmbH & Co. KG

All the players running in the Global Esophagoscope and Gastroscope Market are elaborated thoroughly in the Esophagoscope and Gastroscope Market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Esophagoscope and Gastroscope Market players.

For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/3120

Esophagoscopes and Gastroscopes Market by Product Type:

  • Rigid Endoscopes
  • Flexible Endoscopes

Esophagoscopes and Gastroscopes Market by End User:

  • Esophagoscopes and Gastroscopes for Hospitals
  • Esophagoscopes and Gastroscopes for Ambulatory Surgical Centres
  • Esophagoscopes and Gastroscopes for Specialty Clinics
  • Esophagoscopes and Gastroscopes for Diagnostic Centres

Esophagoscopes and Gastroscopes Market by Region:

  • North America Esophagoscopes and Gastroscopes Market
  • Latin America Esophagoscopes and Gastroscopes Market
  • Europe Esophagoscopes and Gastroscopes Market
  • East Asia Esophagoscopes and Gastroscopes Market
  • South Asia & Pacific Esophagoscopes and Gastroscopes Market
  • Middle East & Africa Esophagoscopes and Gastroscopes Market

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Phenylketonuria Therapeutics Market is projected to grow with an 8.6% CAGR from 2023 to 2033 | FMI

According to a new market research report published by Future Market Insights, the global Phenylketonuria Therapeutics Market is expected to grow at a CAGR of 8.6% during the forecast period of 2023-2033.

Phenylketonuria is an inherited metabolic disorder that affects the way the body processes protein. Patients with PKU are unable to properly break down an amino acid called phenylalanine, which can lead to the build-up of toxic substances in the body. If left untreated, PKU can cause severe intellectual disability, seizures, and other neurological problems.

Get a PDF Sample with the Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16868

The global PKU therapeutics market is driven by a growing awareness of the disease and the availability of advanced treatments. The market is also benefiting from an increasing number of diagnostic tests and genetic screening programs that help identify patients with PKU at an early stage.

The primary treatment for PKU involves a strict, lifelong diet that restricts the intake of phenylalanine. However, many patients find it difficult to adhere to this diet, and as a result, they may require additional treatments. These include medications that help reduce the amount of phenylalanine in the blood, as well as enzyme replacement therapies that help break down phenylalanine more effectively.

It must be noted that the market is set to benefit from the development of new and innovative therapies for PKU. For example, gene therapy is an emerging area of research that aims to correct the genetic defects that cause PKU. Other promising approaches include the use of RNA interference to reduce the production of phenylalanine in the liver, as well as the use of enzyme replacement therapies that are more effective than current treatments.

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-16868

Key Takeaways from the Market Study

  • From 2018 to 2022, the phenylketonuria therapeutics market grew at a CAGR of 5.2%.
  • The global phenylketonuria therapeutics market is expected to grow with an 8.6% CAGR from 2023 to 2033.
  • As of 2033, the phenylketonuria therapeutics market is expected to reach US$ 2.28 Billion.
  • According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
  • North America is expected to possess 40% market share for the Phenylketonuria Therapeutics market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering phenylketonuria therapeutics,” says an FMI analyst.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Cigna, BioMarin Pharmaceuticals, Codexis, Inc., Erytech Pharma, SOM Innovation Biotech SL, Synthetic Biologics, Inc., Retrophin, Inc., Danone, Censa Pharmaceuticals, Homology Medicines, Inc., along with healthcare providers and technology companies among other global players.

  • In January 2023, Jnana Therapeutics was granted clearance by the FDA for its Investigational New Drug (IND) application for JNT-517, a drug being developed to treat phenylketonuria (PKU), a condition that is difficult to treat. The biotechnology company is using its advanced chemoproteomics platform to discover drugs for challenging targets.
  • The Phase 1 program of JNT-517 is currently underway in healthy volunteers in Australia, and will expand to include clinical sites in the U.S. The Phase 1b sub-study will evaluate the drug’s effectiveness in individuals with PKU, with the potential to demonstrate clinical proof of concept that supports a subsequent registrational program.

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16868

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global phenylketonuria therapeutics market, presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of drug type (kuwan and playnziq), route of administration (oral, parenteral, intravenous and subcutaneous), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa).

Key Segments Profiled in the Phenylketonuria Therapeutics Industry Survey

Drug Type:

  • Kuvan
  • Playnziq

Route of Administration:

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 10-years.

Contact:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Optic Neuropathy Management Market value of US$ 7 Billion by registering a CAGR of 5% from 2023 to 2033

According to Future Market Insights, the global Optic Neuropathy Management Market is expected to grow at a CAGR of 5% during the forecast period of 2023 to 2033. The condition can be caused by a variety of factors, including underlying medical conditions such as diabetes, multiple sclerosis, and glaucoma, as well as trauma, infection, and genetic factors.

The global optic neuropathy management market is expected to experience significant growth in the coming years, driven by several factors, including the increasing prevalence of optic neuropathy and underlying medical conditions, advances in technology and research, and growing awareness and understanding of the condition among healthcare providers and the general public.

To Get Sample Copy of Optic Neuropathy Management Market Report with Complete TOC, Figures & Graphs Connect with us at https://www.futuremarketinsights.com/reports/sample/rep-gb-16856

The increasing prevalence of these underlying medical conditions, particularly among the aging population, is contributing to a growing demand for innovative and effective treatments for optic neuropathy. In addition, advances in technology and research are leading to the development of new diagnostic tools and treatment options, including gene therapies, stem cell therapies, and neuroprotective agents, which are expected to improve outcomes for patients with optic neuropathy.

The market for optic neuropathy management is also being driven by the high level of awareness and understanding of the condition among healthcare providers and the general public. This has led to increased diagnosis rates and better management of the condition, which is contributing to improved patient outcomes.

Key Takeaways from the Market Study

  • From 2018 to 2022, the optic neuropathy management market grew at a CAGR of 3.2%.
  • The global optic neuropathy management market is expected to grow with a 5% CAGR from 2023 to 2033.
  • As of 2033, the optic neuropathy management market is expected to reach US$ 7 Billion.
  • According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
  • North America is expected to possess a 40% market share with respect to optic neuropathy management
  • East & South Asia to collectively account for 1/5th of all optic neuropathy management procedures

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-16856

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering optic neuropathy management,” says an FMI analyst

Market Competition

Key players in the market include companies such as Competition Deep Dive, AbbVie Inc., Eli Lily Company, GlaxoSmithKline, Pfizer Inc., Teva Pharmaceuticals, Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi A.S., Bristol-Myers Squibb and Company, along with healthcare providers and technology companies among other global players.

  • In March 2023, Horizon Therapeutics plc released the findings of a study analyzing the real-world use of teprotumumab-trbw (Tepezza, Horizon Therapeutics) in treating Thyroid Eye Disease (TED) patients with dysthyroid optic neuropathy (DON).
  • The study included a majority of patients who had previously not responded to other treatments. DON is a complication of TED that can result in vision loss due to the impairment of visual function caused by thyroid-related optic nerve compression. Teprotumumab-trbw is the only FDA-approved medication for treating TED, which is a rare autoimmune disease that is serious, progressive, and potentially vision-threatening.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global optic neuropathy management market, presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of drug class (corticosteroids, antimetabolites, anticoagulants, serotonin & norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs), route of administration (oral and injectable) and distribution channel (hospital pharmacies, retail pharmacies online pharmacies and drug stores) across seven major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa).

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16856

Key Segments Profiled in the Optic Neuropathy Management Industry Survey

Drug Class:

  • Corticosteroids
  • Antimetabolites
  • Anticoagulants
  • Serotonin and Norepinephrine Reuptake Inhibitors
  • Nonsteroidal Anti-Inflammatory Drugs

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 10-years.

Contact:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs